Novabax, which signed a memorandum of understanding in February to provide a total of 1.1 billion doses, signed a pre-purchase agreement with Covacs for the first tranche.
These will be available from the third quarter of 2021 to 2022, subject to regulatory approval.
The Serum Institute of India plant will manufacture and deliver the remaining 750 million Nova Bucks.
SII is currently creating a dose of AstraZeneca vaccine that is blocked from being exported to Covax due to domestic demand due to a pandemic explosion in India.
Covax was founded to give poor countries fair access to vaccines to combat the coronavirus pandemic.
The facility is jointly led by the World Health Organization (WHO), the Gavi Vaccine Alliance, and the Infectious Disease Control Innovation Alliance.
CEPI invested nearly $ 400 million in Novavax in early 2020 to support the spread of the vaccine.
“Today’s agreement with Novavax is a major step towards Covax’s goal of building the world’s largest and most diverse portfolio of Covid-19 vaccines, with 2 billion safe and effective vaccines in 2021. It’s a big step towards our goal of delivering, “Gavi said. CEO Seth Berkley.
96% Efficacy-Two doses of Novavax The NVX-CoV2373 vaccine injects a fragment of coronavirus to provoke an immune response. Can be stored at normal refrigeration temperature.
The vaccine is currently undergoing separate final-stage population trials in the United States, Mexico, and the United Kingdom, with 100% protection against the development of serious disease and 96.4% efficacy against the original virus strain. Has been demonstrated.
Once the trial is complete, it must be WHO approved before it can be used with Covax.
Novavax was scheduled to hold its first pre-submission meeting with WHO on Friday. This is the first rung for approval by the United Nations Health Organization.
Novavax President Stanley Elk said Thursday’s deal was the culmination of “an urgent mission to deliver large quantities of vaccines to all countries, regardless of income level.”
The agreement includes the opportunity for Covax to access future versions of the vaccine adapted to the new variant.
“In addition, Novavax has agreed to provide additional doses in case the Serum Institute is virtually unable to provide the expected vaccine doses to the Covax facility,” Gavi said.
53 Million Dosages Shipped-Under Covax, the cost of vaccines in the 92 poorest participating countries is covered by donors.
Wealthy countries also use their collective purchasing power to purchase vaccine supplies through their facilities.
Covax has entered into various levels of contracts with AstraZeneca under licenses from SII and its Korean factories. Novavax; Pfizer-BioNTech; Johnson & Johnson; Sanofi-GSK, and Moderna.
Currently, only AstraZeneca and some Pfizer jabs are running the scheme, but the stagnation at SII has dented the program.
To date, the facility has shipped more than 53 million Covid-19 vaccines to 121 participating countries worldwide.
Earlier Thursday, Amnesty International, Human Rights Watch, and Public Citizen, a US consumer rights advocacy group, requested Covax to publish a deal with a jabmaker to ensure transparency.
The group said Covax told them that the contract was commercially confidential and protected under confidentiality obligations.
Novavax signs with Covax in the first 350 million jabs, Health News, ET Health World
Source link Novavax signs with Covax in the first 350 million jabs, Health News, ET Health World